We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bacterial Growth Assay Predicts COVID-19 Severity From Plasma

By LabMedica International staff writers
Posted on 14 Jul 2026

COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. More...

Early differentiation between patients likely to remain mild and those at risk of severe progression is vital for care pathways. Biological samples contain multiplexed chemical signals that may encode this prognostic information. New findings demonstrate that growth responses of Escherichia coli to patient plasma can distinguish mild from severe COVID-19.

INRAE, in collaboration with Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA, describes an approach that uses Escherichia coli (E. coli) as a living bacterial reservoir computer. Without genetic modification, the bacterium is placed in direct contact with plasma from patients with COVID-19. It adapts its metabolism and growth to the plasma’s chemical composition, generating a growth curve that reflects the detected signals.

The resulting growth curve is measured and treated as an information-processing output. In clinical samples, this readout was used to classify whether a patient was likely to develop mild or severe COVID-19. For additional computational tasks, researchers translated problems into defined nutrient mixtures that elicited analogous growth-based responses. Notably, the bacterium performed tasks typically assigned to machine-learning algorithms without prior training.

The research was published in Cell Systems and coordinated by INRAE, with participation from Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA. The authors indicate that genetically unmodified living organisms can convert the complexity of a sample into usable information. This approach could lead to simple, affordable diagnostic and prognostic tools that can be deployed in settings with limited technical resources. 

The team plans to explore additional applications, including monitoring environmental samples such as urban wastewater and analyzing other types of clinical specimens. More broadly, the work highlights the potential of living systems as platforms for information processing and sensing.

Related Links
INRAE 
Grenoble Alpes University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.